Publications
At Phathom, we encourage the publication of scientific information in peer-reviewed publications and at scientific meetings. Key publications of interest are included below.
Some of the publications include data for investigational uses of vonoprazan. Phathom makes no representation as to the safety or efficacy of vonoprazan for investigational uses.
Healing and Maintenance of Healing of Erosive Esophagitis
Alimentary Pharmacology and Therapeutics – 2016
Randomised clinical trial: vonoprazan, a novel potassium‐competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis
Ashida K et al.
World Journal of Gastroenterology – 2018
Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole
Ashida K et al.
Gut – 2020
Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis
Xiao Y et al.
DDW– 2020
Tu1321 – Vonoprazan 10 or 20 mg demonstrated superiority over lanzoprazole 15 mg in preventing relapse in Asian patients with endoscopic healing of erosive esophagitis: A Phase 3, Randomized, Double-Blind, Multicenter Study
Xiao Y et al.
Eradication of H. pylori infection
Gut – 2016
Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study
Murakami K et al.
Alimentary Pharmacology & Therapeutics – 2015
Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects
Jenkins H et al.
Alimentary Pharmacology & Therapeutics – 2015
Acid‐inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects ‐ a randomised open‐label cross‐over study
Sakurai Y et al.
Alimentary Pharmacology & Therapeutics – 2016
Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype
Kagami T et al.
Alimentary Pharmacology & Therapeutics – 2020
Randomised trial of acid inhibition by vonoprazan 10/20 mg once daily vs rabeprazole 10/20 mg twice daily in healthy Japanese volunteers (SAMURAI pH study)
Takeuchi T et al.
Clinical Pharmacology in Drug Development – 2021
The Effect of Food on the Pharmacokinetics of the Potassium-Competitive Acid Blocker Vonoprazan
Darcy M et al.
Scientific Congresses
Analyzing the Relationship Between pH Control and Erosive Esophagitis Healing Rates
DDW – 2023
A Model-Based Meta-Analysis of the Relationship Between pH Control and Erosive Esophagitis Healing Rates
Howden C, et al.
H. Pylori Eradication Rates with Vonoprazan
DDW – 2023
Helicobacter pylori Eradication Rates with Vonoprazan: Subgroup Analysis from the Phase 3 pHalcon-HP Trial
Chey W, et al.
Evaluating Vonoprazan vs. Placebo in the Treatment of Heartburn in NERD
ACG – 2022
Efficacy and Safety of On-Demand Vonoprazan versus Placebo in the Treatment of Heartburn in Symptomatic Nonerosive Reflux Disease (NERD) Patients: A Phase 2 Randomized Controlled Trial
Fass R, et al.
Pharmacodynamics and Pharmacokinetics of Vonoprazan
ACG – 2022
Development and Utilization of a Pharmacokinetic/Pharmacodynamic Model for Vonoprazan to Assess the Relationship Between Dose, Exposure, and pH Holding-Time Ratio
Scarpignato C, et al.
Healthcare Cost Savings Following Successful H. Pylori Eradication
AMCP Nexus – 2022
Healthcare Cost Savings in the Year Following Successful Eradication of Helicobacter pylori With Current US Guideline-Recommended Treatment
Shah S, et al.
Pharmacodynamics and Pharmacokinetics of Vonoprazan
DDW – 2022
Pharmacodynamics and Pharmacokinetics of the Potassium-Competitive Acid Blocker Vonoprazan and the Proton Pump Inhibitor Lansoprazole in U.S. Subjects
Laine L, et al.
Impact of Moderate and Strong CYP3A Inducers on Vonoprazan Exposure
DDW – 2022
Novel Approach to Evaluate the Impact of Moderate and Strong CYP3A Inducers on Vonoprazan Exposure
Ramsden D, et al.
Global Trends in Efficacy of Clarithromycin-Containing Regimens in H. pylori Eradication
DDW – 2022
Global Temporal Trends in the Efficacy of Clarithromycin-Containing Regimens in Helicobacter Pylori Eradication
Moss F S, et al.
Diagnosis and Treatment Patterns Among U.S. H. pylori Patients
DDW – 2022
Diagnosis and Treatment Patterns Among Patients with Helicobacter pylori Infection in the United States: A Linked EMR-Claims Database Analysis
Shah S, et al.
Comparative Efficacy of H. pylori Eradication Therapies
DDW – 2022
Comparative Efficacy of Helicobacter Pylori Eradication Therapies: A Network Meta-Analysis
Malfertheiner P, et al.
Comparative Efficacy of Acid Suppression Backbones for H. pylori Eradication
DDW – 2022
Comparative Efficacy of Acid Suppression Backbones for Helicobacter Pylori Eradication: Results of a Network Meta-Analysis
Malfertheiner P, et al.
Effect of Vonoprazan on the Pharmacokinetics of Midazolam
DDW – 2022
A Clinical Drug Interaction Study to Assess the Effect of Vonoprazan on the Pharmacokinetics of Midazolam
Mulford D J, et al.
The publications contained in this section are provided for informational purposes only. The information contained in each publication is accurate only as of the date it was originally issued and is not controlled by Phathom. Phathom assumes no responsibility for the information or statements in such publications and disavows any obligation to update the information contained in such publications after the date of their issuance.